The DOI matches its OpenAlex record; 4 of the 4 references it cites were found in a registry or an index.
Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme
Abstract
BACKGROUND AND DESIGN: To conduct a prospective case-control study about causative factors of severe bullous erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, we needed to define criteria for classifying the cases and standardize the collection of data so that cases could be reliably diagnosed according to this classification. Based on review of case histories and photographs of patients, a group of experts proposed a classification based on the pattern of erythema multiforme-like lesions (categorized as typical targets, raised or flat atypical targets, and purpuric macules) and on the extent of epidermal detachment. An atlas illustrating this classification that included photographs and schematic drawings was developed. We compared the evaluations of 28 cases by four nonphysicians relying on the atlas with the evaluations of the same cases by five experts not using the atlas to determine the usefulness of this atlas for classifying cases according to our nosologic schema. RESULTS: The following consensus classification in five categories was proposed: bullous erythema multiforme, detachment below 10% of the body surface area plus localized "typical targets" or "raised atypical targets"; Stevens-Johnson syndrome, detachment below 10% of the body surface area plus widespread erythematous or purpuric macules or flat atypical targets; overlap Stevens-Johnson syndrome-toxic epidermal necrolysis, detachment between 10% and 30% of the body surface area plus widespread purpuric macules or flat atypical targets; toxic epidermal necrolysis with spots, detachment above 30% of the body surface area plus widespread purpuric macules or flat atypical targets; and toxic epidermal necrolysis without spots, detachment above 10% of the body surface area with large epidermal sheets and without any purpuric macule or target. Using the atlas, the nonexperts showed excellent agreement with the experts. CONCLUSION: This study suggests that an illustrated atlas is a useful tool for standardizing the diagnosis of acute severe bullous disorders that are attributed to drugs or infectious agents. Whether the five categories proposed represent distinct etiopathologic entities will require further epidemiologic and laboratory investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TOXIC EPIDERMAL NECROLYSIS: AN ERUPTION RESEMBLING SCALDING OF THE SKIN.
LYELL, A. (1956) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1956.tb12766.x · Cited by 720
The estimation of areas of burns
Cc, L. (1944) · Medical Entomology and Zoology · Cited by 560
Toxic epidermal necrolysis (Lyell syndrome)
Roujeau, J.-C., Chosidow, O., Saiag, P., & Guillaume, J.-C. (1990) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(90)70333-d · Cited by 383
Chan, H.-L. (1990) · Archives of Dermatology · doi:10.1001/archderm.1990.01670250049006 · Cited by 371
Cited by
Severe Adverse Cutaneous Reactions to Drugs
Roujeau, J. C., & Stern, R. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311906 · Cited by 1,571
Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis
Roujeau, J.-C., Kelly, J. P., Naldi, L., Rzany, B., Stern, R. S., Anderson, T., Auquier, A., Bastuji-Garin, S., Correia, O., Locati, F., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512143332404 · Cited by 1,465
Self-citationSCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis
Fouchard, N., Bertocchi, M., Roujeau, J.-C., Revuz, J., Wolkenstein, P., & Bastuji-Garin, S. (2000) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2000.00061.x · Cited by 1,199
Self-citationMockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Kardaun, S. H., Sekula, P., Valeyrie-Allanore, L., Liss, Y., Chu, C. Y., Creamer, D., Sidoroff, A., Naldi, L., Mockenhaupt, M., Roujeau, J. C., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12501 · Cited by 1,010
Drug Allergy: An Updated Practice Parameter
(2010) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2010.08.002 · Cited by 957
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Sassolas, B., Haddad, C., Mockenhaupt, M., Dunant, A., Liss, Y., Bork, K., Haustein, U. F., Vieluf, D., Roujeau, J. C., & Le Louet, H. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.252 · Cited by 758
Toxic epidermal necrolysis and Stevens-Johnson syndrome
Harr, T., & French, L. E. (2010) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-5-39 · Cited by 693
Gout: An old disease in new perspective – A review
Ragab, G., Elshahaly, M., & Bardin, T. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.008 · Cited by 599
Drug allergy: A 2022 practice parameter update
Khan, D. A., Banerji, A., Blumenthal, K. G., Phillips, E. J., Solensky, R., White, A. A., Bernstein, J. A., Chu, D. K., Ellis, A. K., Golden, D. B. K., et al. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.08.028 · Cited by 563
Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., Ikezawa, Z., Iijima, M., Shiohara, T., Hashimoto, K., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq537 · Cited by 515
Halevy, S., Ghislain, P.-D., Mockenhaupt, M., Fagot, J.-P., Bouwes Bavinck, J. N., Sidoroff, A., Naldi, L., Dunant, A., Viboud, C., & Roujeau, J.-C. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.08.036 · Cited by 479
Sekula, P., Dunant, A., Mockenhaupt, M., Naldi, L., Bouwes Bavinck, J. N., Halevy, S., Kardaun, S., Sidoroff, A., Liss, Y., Schumacher, M., et al. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.510 · Cited by 448
Ferrell, P. B., & McLeod, H. L. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.10.1543 · Cited by 439
Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
Wolkenstein, P., Latarjet, J., Roujeau, J.-C., Duguet, C., Boudeau, S., Vaillant, L., Maignan, M., Schuhmacher, M.-H., Milpied, B., Pilorget, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02197-7 · Cited by 428
Clinical heterogeneity of drug hypersensitivity
Roujeau, J.-C. (2005) · Toxicology · doi:10.1016/j.tox.2004.12.022 · Cited by 424
Canavan, T. N., Mathes, E. F., Frieden, I., & Shinkai, K. (2015) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.06.026 · Cited by 423
Kaniwa, N., Saito, Y., Aihara, M., Matsunaga, K., Tohkin, M., Kurose, K., Sawada, J.-I., Furuya, H., Takahashi, Y., Muramatsu, M., et al. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.11.1617 · Cited by 410
Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics
Mockenhaupt, M., Messenheimer, J., Tennis, P., & Schlingmann, J. (2005) · Neurology · doi:10.1212/01.wnl.0000156354.20227.f0 · Cited by 399
Epidemiology and risk factors for drug allergy
Thong, B. Y., & Tan, T. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03774.x · Cited by 393
Pereira, F. A., Mudgil, A. V., & Rosmarin, D. M. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.04.048 · Cited by 376
Hsu, D. Y., Brieva, J., Silverberg, N. B., & Silverberg, J. I. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.03.023 · Cited by 376
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Lerch, M., Mainetti, C., Terziroli Beretta-Piccoli, B., & Harr, T. (2018) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-017-8654-z · Cited by 355
Rzany, B., Mockenhaupt, M., Baur, S., Schröder, W., Stocker, U., Mueller, J., Holländer, N., Bruppacher, R., & Schöpf, E. (1996) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(96)00035-2 · Cited by 355
Rzany, B., Correia, O., Kelly, J. P., Naldi, L., Auquier, A., & Stern, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05418-x · Cited by 348
The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis
Mockenhaupt, M. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.66 · Cited by 347
Schwartz, R. A., McDonough, P. H., & Lee, B. W. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.05.002 · Cited by 338
Idiosyncratic drug reactions: the reactive metabolite syndromes
Knowles, S. R., Uetrecht, J., & Shear, N. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03137-8 · Cited by 331
Zimmermann, S., Sekula, P., Venhoff, M., Motschall, E., Knaus, J., Schumacher, M., & Mockenhaupt, M. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2016.5668 · Cited by 328
Prins, C., Kerdel, F. A., Padilla, R. S., Hunziker, T., Chimenti, S., Viard, I., Mauri, D. N., Flynn, K., Trent, J., Margolis, D. J., et al. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.1.26 · Cited by 325
Schwartz, R. A., McDonough, P. H., & Lee, B. W. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.05.003 · Cited by 316
Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature
Letko, E., Papaliodis, D. N., Papaliodis, G. N., Daoud, Y. J., Ahmed, A. R., & Foster, C. S. (2005) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)61112-x · Cited by 316
Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis
PAUL, C., WOLKENSTEIN, P., ADLE, H., WECHSLER, J., GARCHON, H. J., REVUZ, J., & ROUJEAU, J. C. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb06976.x · Cited by 304
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Are Induced by Soluble Fas Ligand
Abe, R., Shimizu, T., Shibaki, A., Nakamura, H., Watanabe, H., & Shimizu, H. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64284-8 · Cited by 301
Drug induced liver injury: an update
Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 286
Creamer, D., Walsh, S. A., Dziewulski, P., Exton, L. S., Lee, H. Y., Dart, J. K. G., Setterfield, J., Bunker, C. B., Ardern‐Jones, M. R., Watson, K. M. T., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14530 · Cited by 277
Takahashi, R., Kano, Y., Yamazaki, Y., Kimishima, M., Mizukawa, Y., & Shiohara, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0804002 · Cited by 276
Levi, N., Bastuji-Garin, S., Mockenhaupt, M., Roujeau, J.-C., Flahault, A., Kelly, J. P., Martin, E., Kaufman, D. W., & Maison, P. (2009) · Pediatrics · doi:10.1542/peds.2008-1923 · Cited by 270
Self-citationToxic Epidermal Necrolysis and Stevens Johnson Syndrome: Our Current Understanding
French, L. E. (2006) · Allergology International · doi:10.2332/allergolint.55.9 · Cited by 263
Genin, E., Chen, D.-P., Hung, S.-I., Sekula, P., Schumacher, M., Chang, P.-Y., Tsai, S.-H., Wu, T.-L., Bellón, T., Tamouza, R., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2013.40 · Cited by 257
Guégan, S., Bastuji-Garin, S., Poszepczynska-Guigné, E., Roujeau, J.-C., & Revuz, J. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700068 · Cited by 253
Self-citationSevere Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study
Dibek Misirlioglu, E., Guvenir, H., Bahceci, S., Haktanir Abul, M., Can, D., Usta Guc, B. E., Erkocoğlu, M., Toyran, M., Nacaroglu, H. T., Civelek, E., et al. (2017) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2017.02.013 · Cited by 96
Chen, K.-T., Twu, S.-J., Chang, H.-J., & Lin, R.-S. (2003) · American Journal of Public Health · doi:10.2105/ajph.93.3.489 · Cited by 54
Clinical manifestations and genetic influences in sulfonamide-induced hypersensitivity
Asyraf, P. A., Kusnadi, I. F., Stefanus, J., Khairinisa, M. A., & Abdulah, R. (2022) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s347522 · Cited by 27
Huang, Y., Wu, C., Chang, T., Peng, C., Lo, G., Hsu, C., Hu, C., & Huang, Y. (2021) · Liver International · doi:10.1111/liv.14990 · Cited by 20
Metadata
- Authors
- Bastuji‐Garin, S.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association
- Published
- 1993-01-01
- Volume
- 129
- Issue
- 1
- Pages
- 92-92
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W2045391651
- Cited by
- 1,697
- References
- 4
- FWCI
- 14.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.